yes, only the overpaid executives voted. In a separate poll, IMGN shareholders think it's the most mismanaged company and should be trading much higher if it were not for the incompetence of Dan Junius and the drug development "leaders".
I hope a light bulb went on when one analyst asked the obvious question during the Charlie Morris presentation, basically, why not just use the proven stuff (linker + DM1 in Kadcyla) and stop fooling around with the stuff that just failed in 901!
How hard can this be, John Lambert and his discovery team have developed at least one linker that has been proven to work and at least one cancer killing agent DM1 that is proven to work, so just link that combo to as many antibodies as you can and make some money for the shareholders, not just the executives. I believe CH or another smart poster suggested this at least a year ago here. Also, now the discovery team has some exciting new linker technology, so IMGN is even more of a value to potential partners and acquirers. For how long will the IMGN shareholders suffer???